/
BNTC
$12.70+$0.33 (+2.67%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$425.0M
34M shares
52-week range
$9.85 – $16.76
41% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.59%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-59.55
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.4M | $17.4M | $97.0K | $59.0K | $73.0K | $75.0K | $0 | $0 |
| Cost of revenue | $243.9K | $304.1K | −$185.0K | $123.0K | $9.0K | $0 | $343.0K | $0 |
| Gross profit | −$39.5K | $7.8M | $282.0K | −$64.0K | $64.0K | $75.0K | −$343.0K | −$396.0K |
| Gross margin | -0.9% | 44.5% | 290.7% | -108.5% | 87.7% | 100.0% | — | — |
| R&D | $3.7M | $3.2M | $3.0M | $7.0M | $11.3M | $12.8M | $15.6M | $18.3M |
| Operating income | −$8.7M | $1.8M | −$8.3M | −$13.6M | −$17.9M | −$19.1M | −$22.5M | −$41.8M |
| EBITDA | −$6.3M | $1.9M | −$7.9M | −$13.5M | −$17.8M | −$18.7M | −$22.1M | −$41.4M |
| Net income | −$6.3M | $1.8M | −$8.3M | −$13.9M | −$18.2M | −$19.6M | −$21.8M | −$37.9M |
| Net margin | -143.0% | 10.5% | -8529.9% | -23528.8% | -24942.5% | -26082.7% | — | — |
| EPS (diluted) | -103.60 | 28.45 | -8.10 | -27.27 | -19.31 | -14.12 | -2.68 | -1.05 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $25M | $-1.02 | $-1.10–$-0.94 | 4 |
| 2027 | $27M | $-0.97 | $-1.05–$-0.88 | 2 |
| 2028 | $71M | $-1.48 | $-1.48–$-1.48 | 1 |
| 2029 | $131M | $-2.23 | $-2.23–$-2.23 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$2.67
Price
$12.70
Implied downside
-79%
Peer comparison
Benitec Biopharma Inc. Common Stock
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
www.benitec.com- Employees
- 19
- IPO / List date
- Jul 11, 2012
- HQ
- HAYWARD, CA
Held by traders on TradeandTell
No one on the platform currently holds BNTC.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in BNTC as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2023-07-26 | 1-for-17reverse |
Recent trades on TradeandTell
No one on the platform has traded BNTC yet.
